Morphic Holding, Inc. announced the presentation of new data, using Spinning Disk Intravital Microscopy (IVM), that provides real-time, in vivo visualization of the impact of a4ß7 inhibition on lymphocyte trafficking in mouse gut-associated lymphoid tissues (GALT). These data were presented in a poster session at Digestive Disease Week (DDW) 2024 meeting. This real-time footage and the associated data for B cell movement clearly demonstrate that MT-108, a potent and selective small molecule a4ß7 inhibitor, leads to increased velocity and flux of rolling lymphocytes.

This activity subsequently prevents lymphocyte migration into gut tissue, including Peyer?s patches, which is a key component of inflammatory bowel disease. Notably, MT-108 impacted B cell trafficking with similar speed of onset and efficacy as the anti-a4ß7 blocking antibody DATK32, a murine analog of the monoclonal antibody vedolizumab. The onset and extent of a4ß7 inhibition can be visualized by the increased velocity of B cells when comparing the lymphocyte movement prior to compound administration.

In the absence of inhibitor, cells are slowed by their binding of a4ß7 with the ligand MAdCAM-1. Following administration of MT-108, the immune cells transit more quickly through the vessel as a result of inhibition of a4ß7-mediated adhesion and fewer cells are seen affixed to vessel walls.